Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial.

Fiche publication

Date publication

décembre 2023

Journal

BMJ oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ADOTEVI Olivier , Pr BORG Christophe , Mme BOUARD Adeline , Dr CURTIT Elsa , Dr MANSI Laura , Dr VERNEREY Dewi , Dr ASGAROV Kamal , Dr LOYON Romain , Dr KROEMER Marie , Dr NARDIN Charlée , Mr FALCOZ Antoine

Tous les auteurs :
Spehner L, Orillard E, Falcoz A, Lepiller Q, Bouard A, Almotlak H, Kim S, Curtit E, Meynard G, Jary M, Nardin C, Asgarov K, Abdeljaoued S, Chartral U, Mougey V, Ben Khelil M, Lopez M, Loyon R, Vernerey D, Adotevi O, Borg C, Mansi L, Kroemer M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39886486

Résumé

Vaccinated patients with cancer in follow-up studies showed a high seropositivity rate but impaired antibody titres and T cell responses following mRNA vaccine against COVID-19. Besides clinical characteristics and the type of anticancer treatment before vaccination, the identification of patients susceptible to non-response following vaccination using immunological markers is worth to be investigated.